Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
liposomal irinotecan + ramucirumab
- Development stage
- Unknown
- Lead developer
- Ipsen
- Modality
- Nanoparticles → Drug Delivery Systems, Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
Liposomal irinotecan + ramucirumab is a combination therapy being evaluated for the treatment of advanced gastric adenocarcinoma and gastroesophageal junction adenocarcinoma. Liposomal irinotecan (Onivyde, MM-398) is a topoisomerase I inhibitor encapsulated in a long-circulating liposomal nanoparticle, which improves drug delivery to tumor tissues and extends the half-life of the active metabolite, SN-38. Ramucirumab (Cyramza) is a recombinant human IgG1 monoclonal antibody that specifically binds to vascular endothelial growth factor receptor 2 (VEGFR2), blocking the binding of VEGF ligands and inhibiting tumor angiogenesis. This combination is being studied, notably in trials led by the University of Southern California, as a second-line treatment option for patients who have progressed on platinum-based chemotherapy.
- Brand names
- OnivydeCyramza
- Other names
- nanoliposomal irinotecanMM-398 + ramucirumabnal-IRI + ramucirumabOnivyde + Cyramza
02
Targets
VEGFR2 (Vascular endothelial growth factor receptor 2)TOP1 (DNA Topoisomerase I)
Beyond the preview
Go deeper on liposomal irinotecan + ramucirumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on liposomal irinotecan + ramucirumab.